Finland· FI-REL-REL62844
TEPEZZA
A teprotumumab product containing teprotumumab, registered in Finland by Amgen Europe B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Teprotumumab is registered in 10 of 19 countries.
Countries holding a registration under ATC L04AG13 (teprotumumab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Teprotumumab · ATC L04AG13
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Teprotumumab
- Manufacturer
- Amgen Europe B.V.
- Country
- Finland (FI)
- ATC code
- L04AG13
- ATC class
- Teprotumumab
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
55 interactions on record for teprotumumab.
Graded by severity as the source publishes them — 55 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Teprotumumab · interactions on record
55 records
- 55 moderate
Most severe, free to view
- LiraglutidA08AX02moderate
- SemaglutidA08AX03moderate
- Insulin (human)A10AB01moderate
- Insulin lisproA10AB04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Teprotumumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTepezza 500 mgAmgen Europe
- SwitzerlandTepezza 500 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungAmgen Switzerland AG
- CzechiaTEPEZZAAmgen Europe B.V., Breda
- SpainTEPEZZA 500 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- United KingdomTepezza 500mg powder for concentrate for solution for infusion vialsAmgen Ltd
- IrelandTEPEZZA 500 mg powder for concentrate for solution for infusionAmgen Europe B.V.,
- IcelandTepezzaAmgen Europe B.V.*
- PolandTepezzaAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tepezza
- Norway · Tepezza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5580a0c7-660c-4553-861a-4774bfbaee61 GET /v1/drugs/5580a0c7-660c-4553-861a-4774bfbaee61?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "500 mg",
"atc_label": "teprotumumabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/25/1941/001",
"fimea_rel_id": "REL62844",
"authorised_at": "2025-06-19"
}See everything about teprotumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.